Amgen Inc. (AMGN)
Largest Insider Buys in Sector
AMGN Stock Price History Chart
AMGN Stock Performance
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment …
Insider Activity of Amgen Inc.
Over the last 12 months, insiders at Amgen Inc. have bought $0 and sold $1.24M worth of Amgen Inc. stock.
On average, over the past 5 years, insiders at Amgen Inc. have bought $0 and sold $6.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,020 shares for transaction amount of $1M was made by Hassan Fred (director) on 2015‑08‑19.
List of Insider Buy and Sell Transactions, Amgen Inc.
| 2024-05-03 | Sale | SVP & CCO | 2,117 0.0004% | $313.09 | $662,802 | +2.75% | ||
| 2023-12-04 | Sale | SVP & CCO | 2,096 0.0004% | $273.03 | $572,276 | +12.16% | ||
| 2023-11-08 | Sale | EVP, Gen. Counsel & Secy. | 10,000 0.0019% | $272.81 | $2.73M | +11.12% | ||
| 2023-08-10 | Sale | EVP, Global Commercial Ops | 9,558 0.0018% | $262.43 | $2.51M | +5.68% | ||
| 2022-11-09 | Sale | SVP, Business Development | 387 <0.0001% | $292.90 | $113,352 | -11.93% | ||
| 2022-11-08 | Sale | SVP & CCO | 545 0.0001% | $293.54 | $159,977 | -12.76% | ||
| 2022-08-22 | Sale | 200 <0.0001% | $249.96 | $49,992 | -1.11% | |||
| 2022-08-18 | Sale | 6,600 0.0012% | $249.00 | $1.64M | -2.22% | |||
| 2022-05-23 | Sale | 1,200 0.0002% | $250.00 | $300,000 | -0.65% | |||
| 2022-05-10 | Sale | EVP, Gen. Counsel & Secy. | 27,000 0.0051% | $241.81 | $6.53M | +3.63% | ||
| 2021-05-12 | Sale | director | 2,000 0.0002% | $161.12 | $322,230 | -6.81% | ||
| 2021-05-11 | Sale | SVP & CCO | 5,000 0.0007% | $207.55 | $1.04M | -7.35% | ||
| 2021-05-07 | Sale | director | 500 <0.0001% | $251.78 | $125,890 | -8.09% | ||
| 2021-04-14 | Sale | director | 2,000 0.0002% | $160.81 | $321,620 | -6.30% | ||
| 2021-03-10 | Sale | director | 2,000 0.0002% | $151.59 | $303,170 | +1.39% | ||
| 2021-02-10 | Sale | director | 2,000 0.0002% | $155.02 | $310,040 | -1.80% | ||
| 2021-02-08 | Sale | director | 500 <0.0001% | $119.00 | $59,498 | -1.43% | ||
| 2021-02-04 | Sale | EVP, Gen. Counsel & Secy. | 22,220 0.0038% | $236.51 | $5.26M | -1.28% | ||
| 2021-01-13 | Sale | director | 2,000 0.0002% | $118.00 | $235,990 | -0.60% | ||
| 2020-11-09 | Sale | director | 500 <0.0001% | $121.20 | $60,600 | +1.39% |
Insider Historical Profitability
| Bradway Robert A | Chairman, CEO and President | 383102 0.0713% | $294.53 | 1 | 2 | +39.22% |
| MORROW GEORGE J | Exe VP, Global Commercial Ops | 93719 0.0174% | $294.53 | 1 | 4 | <0.0001% |
| CHOATE JERRY D | director | 48575 0.009% | $294.53 | 1 | 2 | <0.0001% |
| GLUCK FREDERICK W | director | 15748 0.0029% | $294.53 | 1 | 3 | <0.0001% |
| de Carbonnel Francois | director | 15528 0.0029% | $294.53 | 2 | 4 | +16.13% |
Institutional Investor Ownership
| The Vanguard Group | $14.81B | 9.71 | 52.09M | +6.21% | +$865.94M | 0.27 | |
| BlackRock | $13.64B | 8.94 | 47.97M | +0.33% | +$45.12M | 0.3 | |
| State Street | $8.28B | 5.43 | 29.13M | -1.13% | -$94.3M | 0.34 | |
| PRIMECAP Management Co | $4.15B | 2.72 | 14.6M | +0.07% | +$2.98M | 3.05 | |
| Morgan Stanley | $3.97B | 2.61 | 13.97M | -3.2% | -$131.38M | 0.29 |